Wegovy vs Ozempic: 5x Higher Risk of Vision Loss?

The growing popularity of GLP-1 receptor agonists like semaglutide (marketed as Wegovy and Ozempic) for weight management and diabetes treatment has prompted increased scrutiny of potential side effects beyond the commonly reported gastrointestinal issues. Recent research highlights a concerning link between these medications and an increased risk of ischemic optic neuropathy (ION), a condition that can lead to sudden vision loss.

Specifically, a study published in the British Journal of Ophthalmology found that individuals using Wegovy had approximately five times the risk of developing ION compared to those taking Ozempic. This disparity is likely linked to the higher dosage of semaglutide used in Wegovy, which is prescribed for weight loss, while Ozempic is typically used for managing type 2 diabetes.

Researchers analyzing data from the FDA Adverse Event Reporting System (FAERS) between December 2017 and December 2024 observed this increased risk. The study also indicated that men may be at a nearly three times higher risk of ION compared to women.

ION encompasses a group of conditions, including non-arteritic anterior ischemic optic neuropathy (NAION), characterized by reduced blood flow to the optic nerve. This disruption can cause sudden, often permanent, vision loss. While relatively rare, affecting around one in 10,000 people taking semaglutide, the potential for a dose-dependent safety concern is being investigated.

Symptoms of ION can include sudden blurred vision or vision loss in one eye, difficulty perceiving colors, and pain with eye movement. Prompt medical attention is crucial if any of these symptoms arise.

The recent findings are prompting a wave of further investigation into the relationship between GLP-1 medications and eye health. Several key areas are likely to see increased focus:

• Dose-Response Relationship: Researchers will continue to explore whether a direct correlation exists between the dosage of semaglutide and the risk of ION.
• Sex-Based Differences: The observed higher risk in men warrants further study to understand the underlying biological mechanisms contributing to this disparity.
• Long-Term Monitoring: Establishing long-term monitoring protocols for patients on GLP-1 medications to detect early signs of optic nerve damage is crucial.
• Comparative Studies: Conducting comparative studies between different GLP-1 agonists (Wegovy, Ozempic, Rybelsus, Mounjaro) to assess their respective risk profiles.
• Underlying Risk Factors: Investigating whether pre-existing vascular or metabolic conditions increase susceptibility to ION in individuals taking these medications.

The FDA is also expected to continue monitoring adverse event reports and may issue further guidance to healthcare providers, and patients.

If you are currently taking Wegovy or Ozempic, it’s important to be aware of the potential risk of ION and to report any sudden changes in vision to your healthcare provider immediately. Do not discontinue medication without consulting your doctor.

Individuals with pre-existing risk factors for vascular disease or optic nerve disorders should discuss these concerns with their physician before starting GLP-1 therapy.

What is ION?

ION, or ischemic optic neuropathy, is a condition where blood flow to the optic nerve is disrupted, potentially leading to sudden vision loss.

Is Wegovy safe?

Wegovy is generally considered safe for appropriate leverage, but recent studies suggest a higher risk of ION compared to Ozempic.

Are men at higher risk?

Yes, research indicates that men taking Wegovy may have a nearly three times higher risk of developing ION than women.

What should I do if I experience vision changes?

Report any sudden changes in vision to your healthcare provider immediately.